TH48585A - Components and methods for the prevention and treatment of sexual dysfunction. - Google Patents

Abstract

DC60 (27/06/43) This invention describes a method for the prevention and treatment of degeneration. Erectile dysfunction in male patients, and Women by oral administration, at a minimum, an alpha-adrenaline-induced cell group antagonist. (Alpha-adrenergic receptor antagonist) one and at least the substance Is one that stimulates intracellular nitric oxide (endogenous nitric oxide), or a loosening factor obtained from Endothelium This is an endothelium-derived relaxing factor in living bodies (in vivo), or as an enzyme for an enzyme that stimulates nitric oxide synthase (a substrate for nitric oxide synthase). Described the components that can be administered as a minimum, An alpha-adrenergic receptor antagonist, and at least one antagonist, is an alpha-adrenergic receptor antagonist. One that stimulates nitric out Endogenous nitric oxide (endogenous nitric oxide) or loosening factor obtained from endothelium (endothelium-derived relaxing factor) in the body of living organisms (in vivo) or substances that tend to Sime has an effect on The enzyme that stimulates the synthesis of nitric oxide (a substrate for nitric oxide synthase). Alpha-adrenergic (alpha-adrenergic receptor antagonist) is usually yohimbine or fennolamin. (phentolamine) and compounds that activate intracellular nitric oxide (endogenous nitric oxide) or loosening factor obtained from endothelium. (endothelium-derived relaxing factor) in living bodies (in vivo) or enzymes for enzymes that stimulate nitric oxide synthase (a substrate for nitric oxide synthase), usually L- Arginine (L-arginine) in the referenced form. This invention provides an enveloping envelope. Contains a single dose of a single dose of the drug L-arginine and / or a salt that is acceptable via Pharmacy of the substance and yohimbine and / or its salt are acceptable. Pharmacy of substances This invention describes methods for the prevention and treatment of degeneration. Erectile dysfunction in male patients, and Women by oral administration, at least, an alpha-adrenaline-induced cell group antagonist. (Alpha-adrenergic receptor antagonist) one and at least the substance Is one that stimulates intracellular nitric oxide (endogenous nitric oxide), or a loosening factor obtained from Endothelium This is an endothelim-derived relaxing factor in living bodies (in vivo), or as an active enzyme for an enzyme that stimulates nitric oxide synthase (a substrate for nitric oxide synthase). Describes the components that can be administered as at least An alpha-adrenergic receptor antagonist, and at least one antagonist, is an alpha-adrenergic receptor antagonist. One that stimulates nitric out Endogenous nitric oxide (endogenous nitric oxide) or loosening factor obtained from endothelium (endothelium-derived relaxing factor) in the body of living organisms (in vivo) or as a substance that Side effects on For the enzyme that stimulates the synthesis of nitric oxide (alpha substrate for nitric oxide synthase), in this invention, a stimulating cell group antagonist. Alpha-adrenergic (alpha-adrenergic receptor antagonist) is usually yohimbine or fenolamine. (phentolamine) and compounds that activate intracellular nitric oxide (endogenous nitric oxide) or loosening factor obtained from endothelium. (endothelium-derived relaxing factor) in living bodies (in vivo), or as an enzyme for enzymes that stimulate nitric oxide synthase (a substrate for nitric oxide synthase), usually L. - Arginine (L-arginine) in the referred form. This invention provides an enveloping envelope. Contains a single dose of a single dose of the drug L-arginine and / or a salt that is acceptable via Pharmacy of the substance and yohimbine and / or its salt are acceptable. Pharmacy of substances

Claims (2)

1. Encapsulated sachet containing a single dose component of a receptor drug. Presented containing L-arginine and / or pharmacologically acceptable salts. Approximately 1 g to approximately 10 g depends on free-base form of L-arginine and yohimbine or acceptable salts in amounts of 1 mg to approximately 18 mg based on free form of yohimbine. 2. Envelop of Clause 1 where L-arginine and / or salt are tagged: